News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,762 Results
Type
Article (8016)
Company Profile (141)
Press Release (477874)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166738)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52873)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238191)
Policy (17898)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33140)
ALS (109)
Alzheimer's disease (984)
Antibody-drug conjugate (ADC) (284)
Approvals (10399)
Artificial intelligence (335)
ASCO (159)
Autoimmune disease (220)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6952)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (1)
Bladder cancer (139)
Brain cancer (31)
Breast cancer (521)
Cancer (3763)
Cardiovascular disease (226)
Career advice (242)
Career pathing (1)
CAR-T (178)
CDC (1)
CDMO (17)
Celiac Disease (1)
Cell therapy (488)
Cervical cancer (35)
Clinical research (47976)
Collaboration (1280)
Commercialization (3)
Compensation (1536)
Complete response letters (34)
COVID-19 (759)
CRISPR (64)
C-suite (804)
Cystic fibrosis (87)
Data (5859)
Denatured (4)
Depression (107)
Dermatology (67)
Diabetes (355)
Diagnostics (4220)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (159)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73745)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88091)
Executive appointments (713)
FDA (12479)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (945)
Gene editing (126)
Generative AI (11)
Gene therapy (333)
GLP-1 (294)
Government (944)
Grass and pollen (2)
Guidances (281)
Healthcare (9362)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (107)
Immuno-oncology (61)
Indications (164)
Infectious disease (951)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (262)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1967)
Job search strategy (232)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5194)
Licensing (19)
Liver cancer (45)
Longevity (19)
Lung cancer (543)
Lymphoma (257)
Machine learning (29)
Management (3)
Manufacturing (567)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8673)
Medtech (8832)
Mergers & acquisitions (14409)
Metabolic disorders (727)
mRNA (63)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (228)
Neuropsychiatric disorders (40)
Neuroscience (1875)
NextGen: Class of 2026 (3147)
Non-profit (843)
Obesity (231)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (206)
Parkinson's disease (206)
Partnered (12)
Patents (499)
Patient recruitment (531)
Patient selection (2)
Peanut (32)
People (41350)
Peptides (2)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15507)
Phase 2 (21432)
Phase 3 (14437)
Pipeline (7702)
Policy (18)
Postmarket research (1559)
Preclinical (6551)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (195)
Rare diseases (589)
Real estate (3021)
Recruiting (6)
Regenerative medicine (2)
Regulatory (14933)
Reports (23)
Research institute (583)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (104)
Series A (163)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (51)
Vaccines (320)
Venture capital (17)
Weight loss (75)
Women's health (89)
Date
Today (48)
Last 7 days (260)
Last 30 days (1376)
Last 365 days (19052)
2026 (13671)
2025 (19251)
2024 (22986)
2023 (26538)
2022 (34586)
2021 (37150)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24247)
2014 (21675)
2013 (18135)
2012 (20202)
2011 (20440)
2010 (20332)
Location
Africa (229)
Alabama (78)
Alaska (2)
Arizona (311)
Arkansas (11)
Asia (17964)
Australia (2108)
California (12358)
Canada (3240)
China (545)
Colorado (497)
Connecticut (427)
Delaware (214)
Europe (24692)
Florida (1857)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (728)
India (52)
Indiana (324)
Iowa (16)
Japan (426)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1232)
Massachusetts (8105)
Michigan (314)
Minnesota (572)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (123)
New Hampshire (60)
New Jersey (2699)
New Mexico (12)
New York (2899)
North Carolina (1317)
North Dakota (4)
Northern California (6216)
Ohio (295)
Oklahoma (14)
Oregon (16)
Pennsylvania (2297)
Puerto Rico (21)
Rhode Island (30)
South America (406)
South Carolina (78)
South Dakota (1)
Southern California (5144)
Tennessee (125)
Texas (2005)
United States (40058)
Utah (374)
Vermont (1)
Virginia (159)
Washington D.C. (38)
Washington State (956)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,762 Results for "neucyte inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
NeuCyte and Mount Sinai Enter Collaboration Agreement
NeuCyte, Inc. , an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai. The Seaver Center is collabor
January 19, 2021
·
3 min read
Business
NeuCyte and REPROCELL enter distribution agreement in North America and Europe
This new distributorship will grant REPROCELL customers access to NeuCyte’s pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements.
September 25, 2019
·
2 min read
Biotech Bay
NeuCyte Inc. Closes $6.7 Million Series A Financing
SUNNYVALE, Calif., May 8, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced the closing of a Series A financing round of $6.7 million, for a totaled funding of more than $8 million. NeuCyte’s initial investors, Cowin Venture and Leaguer Ventures, led the round.
May 8, 2018
·
4 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
Allumiqs Solutions Inc. and Allumiqs Corporation
September 15, 2026
·
1 min read
Business
NeuCyte Licenses Promising Novel Compound for Treatment of Refractory Epilepsy and Related Neurological Disorders
NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into an exclusive license agreement with Trillium Therapeutics to advance an undisclosed preclinical compound with potential utility in treating refractory epilepsy in the form of Dravet syndrome and related disorders.
September 24, 2019
·
3 min read
Press Releases
Carlsmed, Inc. Announces Chief Operating Officer Appointment
September 8, 2026
·
2 min read
Press Releases
Glucotrack, Inc. Announces Reverse Stock Split
August 27, 2026
·
6 min read
Press Releases
PostEra’s Fertility programs acquired by EMD Serono, Inc.
September 9, 2026
·
2 min read
Press Releases
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026
·
12 min read
1 of 48,577
Next
